Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charles Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander, Tamar Safra, Ignace Vergote, Mark Wickens, Elizabeth S Lowe, James Carmichael, Bella Kaufman

Research output: Contribution to journalArticlepeer-review

Abstract

Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clinical efficacy in nonrandomized phase II trials in patients with ovarian cancer with BRCA1 or BRCA2 deficiency. We assessed the comparative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.
Original languageEnglish
Pages (from-to)372-9
Number of pages8
JournalJournal of Clinical Oncology
Volume30
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint Dive into the research topics of 'Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this